URGN
UroGen Pharma Ltd
NASDAQ: URGN · HEALTHCARE · BIOTECHNOLOGY
$23.83
+2.10% today
Updated 2026-04-30
Market cap
$1.14B
P/E ratio
—
P/S ratio
10.35x
EPS (TTM)
$-3.19
Dividend yield
—
52W range
$3 – $30
Volume
0.8M
UroGen Pharma Ltd (URGN) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-139.80%
Operating margin
-50.50%
ROE
-1,481.00%
ROA
-32.10%
Debt/equity
-1.13x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $0.00 | $-3.31M | — | — | — |
| 2014 | $0.00 | $-4.56M | — | — | — |
| 2015 | $0.00 | $-12.69M | — | — | — |
| 2016 | $17.53M | $-1.94M | 99.84% | 4.55% | -11.07% |
| 2017 | $8.16M | $-20.00M | 92.65% | -244.55% | -245.16% |
| 2018 | $1.13M | $-75.66M | -59.84% | -6,842.20% | -6,707.18% |
| 2019 | $18000.00 | $-105.15M | 100.00% | -608,211.11% | -584,144.44% |
| 2020 | $11.80M | $-128.48M | 91.45% | -1,074.15% | -1,088.94% |
| 2021 | $48.04M | $-110.82M | 89.27% | -192.11% | -230.67% |
| 2022 | $64.36M | $-109.78M | 88.11% | -122.82% | -170.58% |
| 2023 | $82.71M | $-102.24M | 88.68% | -79.23% | -123.61% |
| 2024 | $90.40M | $-126.87M | 90.18% | -107.06% | -140.35% |
| 2025 | $109.79M | $-153.49M | 88.66% | -113.73% | -139.81% |